Health Catalyst Future Growth
Future criteria checks 1/6
Health Catalyst is forecast to grow earnings and revenue by 28.8% and 10.5% per annum respectively. EPS is expected to grow by 34.3% per annum. Return on equity is forecast to be 9.7% in 3 years.
Key information
28.8%
Earnings growth rate
34.3%
EPS growth rate
| Healthcare Services earnings growth | 32.4% |
| Revenue growth rate | 10.5% |
| Future return on equity | 9.7% |
| Analyst coverage | Good |
| Last updated | 06 Dec 2024 |
Recent future growth updates
Recent updates
Health Catalyst: Improved Demand Environment Reinforces My Buy Rating
Dec 18Health Catalyst: Still Optimistic On Achieving Adjusted EBITDA Targets
Sep 24Health Catalyst, Inc.'s (NASDAQ:HCAT) Shares Lagging The Industry But So Is The Business
Jul 17
Health Catalyst: Stellar Earnings Growth Projected
Jun 26Health Catalyst, Inc. (NASDAQ:HCAT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 12Benign Growth For Health Catalyst, Inc. (NASDAQ:HCAT) Underpins Its Share Price
Apr 04Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible
Mar 09Health Catalyst Looks To Slim Down As It Faces Industry Headwinds (Downgrade)
Feb 16Is Health Catalyst (NASDAQ:HCAT) A Risky Investment?
Jan 27What Health Catalyst, Inc.'s (NASDAQ:HCAT) 25% Share Price Gain Is Not Telling You
Dec 24Is Health Catalyst, Inc. (NASDAQ:HCAT) Trading At A 47% Discount?
Dec 15Is Health Catalyst (NASDAQ:HCAT) Weighed On By Its Debt Load?
Oct 24Subdued Growth No Barrier To Health Catalyst, Inc.'s (NASDAQ:HCAT) Price
Jul 31Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Jun 27Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Feb 22Health Catalyst, Inc. (NASDAQ:HCAT) Shares Could Be 22% Above Their Intrinsic Value Estimate
Dec 06Is Health Catalyst (NASDAQ:HCAT) Using Debt In A Risky Way?
Nov 03Health Catalyst: Looking For A Turnaround For This 'Bio Boom' Candidate
Oct 14Health Catalyst names Kevin Freeman as Chief Growth Officer, Tarah Bryan as Chief Marketing Officer, Dave Ross as Chief Technology Officer
Sep 07Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 381 | -38 | 13 | 48 | 10 |
| 12/31/2025 | 342 | -48 | -6 | 29 | 14 |
| 12/31/2024 | 308 | -62 | 9 | 16 | 14 |
| 9/30/2024 | 302 | -79 | -16 | -1 | N/A |
| 6/30/2024 | 299 | -86 | -17 | -4 | N/A |
| 3/31/2024 | 297 | -106 | -31 | -17 | N/A |
| 12/31/2023 | 296 | -118 | -47 | -33 | N/A |
| 9/30/2023 | 290 | -124 | -44 | -29 | N/A |
| 6/30/2023 | 285 | -147 | -61 | -44 | N/A |
| 3/31/2023 | 282 | -148 | -59 | -42 | N/A |
| 12/31/2022 | 276 | -137 | -53 | -35 | N/A |
| 9/30/2022 | 272 | -151 | -47 | -30 | N/A |
| 6/30/2022 | 265 | -145 | -40 | -24 | N/A |
| 3/31/2022 | 254 | -147 | -34 | -19 | N/A |
| 12/31/2021 | 242 | -153 | -42 | -23 | N/A |
| 9/30/2021 | 230 | -147 | -39 | -17 | N/A |
| 6/30/2021 | 216 | -135 | -36 | -17 | N/A |
| 3/31/2021 | 200 | -126 | -29 | -13 | N/A |
| 12/31/2020 | 189 | -115 | -37 | -26 | N/A |
| 9/30/2020 | 179 | -86 | -39 | -35 | N/A |
| 6/30/2020 | 171 | -99 | -41 | -36 | N/A |
| 3/31/2020 | 165 | -181 | -48 | -44 | N/A |
| 12/31/2019 | 155 | -241 | -37 | -32 | N/A |
| 9/30/2019 | 148 | -304 | -37 | -32 | N/A |
| 6/30/2019 | 141 | -282 | -37 | -33 | N/A |
| 3/31/2019 | 127 | -190 | -41 | -38 | N/A |
| 12/31/2018 | 113 | -114 | -43 | -40 | N/A |
| 12/31/2017 | 73 | -59 | N/A | -37 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HCAT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HCAT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HCAT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HCAT's revenue (10.5% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: HCAT's revenue (10.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HCAT's Return on Equity is forecast to be low in 3 years time (9.7%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 13:01 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Health Catalyst, Inc. is covered by 22 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhilin Long | Berenberg |
| David Larsen | BTIG |
| Richard Close | Canaccord Genuity |